Skip to main content
Bo Chen, MD, Pathology, Birmingham, AL

BoChenMD

Pathology Birmingham, AL

Anatomic Pathology, Clinical Pathology

Physician

Are you Dr. Chen?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 4 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    619 19th St S
    Birmingham, AL 35233
    Phone+1 205-934-4011

Summary

  • Dr. Bo Chen, MD is a board certified pathologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Florida, and Pennsylvania. He is affiliated with University of Alabama Hospital.

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterResidency, Pathology-Anatomic and Clinical, 2016 - 2020
  • Qingdao University Medical College
    Qingdao University Medical CollegeClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - 2026
  • PA State Medical License
    PA State Medical License 2021 - 2022
  • AL State Medical License
    AL State Medical License 2018 - 2021
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical

Publications & Presentations

PubMed

Press Mentions

  • Development of Prognosis Model for Colon Cancer Based on Autophagy-Related Genes
    Development of Prognosis Model for Colon Cancer Based on Autophagy-Related GenesOctober 30th, 2020
  • Cocaine-Induced Neural Adaptations in the Lateral Hypothalamic Melanin-Concentrating Hormone Neurons and the Role in Regulating Rapid Eye Movement Sleep After Withdrawal
    Cocaine-Induced Neural Adaptations in the Lateral Hypothalamic Melanin-Concentrating Hormone Neurons and the Role in Regulating Rapid Eye Movement Sleep After WithdrawalOctober 22nd, 2020
  • miR-200c Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+ Breast Cancer
    miR-200c Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+ Breast CancerOctober 10th, 2019